 | |
| Company type | Public (NYSE: TMO) |
|---|---|
| Headquarters | Waltham, Massachusetts, USA |
Key people | Marc N. Casper (President & CEO) |
| Website | www.thermofisher.com |
Navigenics, Inc. was a privately held personal genomics company, based in Foster City, California, that used genetic testing to help people determine their individual risk for dozens of health conditions. [1]
Navigenics was co-founded in 2006 by David Agus, M.D., a prostate cancer specialist who is a professor of medicine at the University of Southern California and director of the USC Center for Applied Molecular Medicine and the USC Westside Prostate Cancer Center in Los Angeles, and Dietrich Stephan, Ph.D., member of the board of directors of the Personalized Medicine Coalition, current CEO of Silicon Valley Biosystems, former chairman of Neurogenomics and deputy director for discovery research at the Translational Genomics Research Institute. [2]
In July 2012, Navigenics was acquired by Life Technologies, [3] which was acquired by Thermo Fisher Scientific in February, 2014.
In June 2008, California health regulators sent cease-and-desist letters to Navigenics and 12 other genetic testing firms, including 23andMe. [4] The state regulators asked the companies to prove a physician was involved in the ordering of each test and that state clinical laboratory licensing requirements were being fulfilled. The controversy sparked a flurry of interest in the relatively new field, as well as a number of media articles, including an opinion piece on Wired.com entitled, “Attention, California Health Dept.: My DNA Is My Data.” [5] In August 2008, Navigenics and 23andMe received state licenses allowing the companies to continue to do business in California. [6]
Genetic testing, also known as DNA testing, is used to identify changes in DNA sequence or chromosome structure. Genetic testing can also include measuring the results of genetic changes, such as RNA analysis as an output of gene expression, or through biochemical analysis to measure specific protein output. In a medical setting, genetic testing can be used to diagnose or rule out suspected genetic disorders, predict risks for specific conditions, or gain information that can be used to customize medical treatments based on an individual's genetic makeup. Genetic testing can also be used to determine biological relatives, such as a child's biological parentage through DNA paternity testing, or be used to broadly predict an individual's ancestry. Genetic testing of plants and animals can be used for similar reasons as in humans, to gain information used for selective breeding, or for efforts to boost genetic diversity in endangered populations.
deCODE genetics is a biopharmaceutical company based in Reykjavík, Iceland. The company was founded in 1996 by Kári Stefánsson with the aim of using population genetics studies to identify variations in the human genome associated with common diseases, and to apply these discoveries "to develop novel methods to identify, treat and prevent diseases."
Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept, though some authors and organizations differentiate between these expressions based on particular nuances. P4 is short for "predictive, preventive, personalized and participatory".
Genetic discrimination occurs when people treat others differently because they have or are perceived to have a gene mutation(s) that causes or increases the risk of an inherited disorder. It may also refer to any and all discrimination based on the genotype of a person rather than their individual merits, including that related to race, although the latter would be more appropriately included under racial discrimination. Some legal scholars have argued for a more precise and broader definition of genetic discrimination: "Genetic discrimination should be defined as when an individual is subjected to negative treatment, not as a result of the individual's physical manifestation of disease or disability, but solely because of the individual's genetic composition." Genetic Discrimination is considered to have its foundations in genetic determinism and genetic essentialism, and is based on the concept of genism, i.e. distinctive human characteristics and capacities are determined by genes.
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Anne E. Wojcicki is an American entrepreneur who co-founded and is CEO of the personal genomics company 23andMe. She founded the company in 2006 with Linda Avey and Paul Cusenza. She is a co-founder and board member of the Breakthrough Prize.
Rick Antonius Kittles is an American biologist specializing in human genetics and a Senior Vice President for Research at the Morehouse School of Medicine. He is of African-American ancestry, and achieved renown in the 1990s for his pioneering work in tracing the ancestry of African Americans via DNA testing.
DNAPrint Genomics was a genetics company with a wide range of products related to genetic profiling. They were the first company to introduce forensic and consumer genomics products, which were developed immediately upon the publication of the first complete draft of the human genome in the early 2000s. They researched, developed, and marketed the first ever consumer genomics product, based on "Ancestry Informative Markers" which they used to correctly identify the BioGeographical Ancestry (BGA) of a human based on a sample of their DNA. They also researched, developed and marketed the first ever forensic genomics product - DNAWITNESS - which was used to create a physical profile of donors of crime scene DNA. The company reached a peak of roughly $3M/year revenues but ceased operations in February 2009.
Personal genomics or consumer genetics is the branch of genomics concerned with the sequencing, analysis and interpretation of the genome of an individual. The genotyping stage employs different techniques, including single-nucleotide polymorphism (SNP) analysis chips, or partial or full genome sequencing. Once the genotypes are known, the individual's variations can be compared with the published literature to determine likelihood of trait expression, ancestry inference and disease risk.
SNPedia is a wiki-based bioinformatics web site that serves as a database of single nucleotide polymorphisms (SNPs). Each article on a SNP provides a short description, links to scientific articles and personal genomics web sites, as well as microarray information about that SNP. Thus SNPedia may support the interpretation of results of personal genotyping from, e.g., 23andMe and similar companies.
Dr. Paul R. Billings is a distinguished American doctor, lecturer, researcher, professor, and consultant on genetic information. His research interests include the impact of genomic data on society, the integration of genomics with diagnostics in health and medical care, and individualised genomic medicine. He is the author of over 250 publications and has appeared on talk shows such as The Oprah Winfrey Show and 60 Minutes. He is currently the CEO and Director of Biological Dynamics.
Dietrich A. Stephan is an American human geneticist and entrepreneur who works in personalized medicine. Stephan is currently CEO of NeuBase Therapeutics and a General Partner in Cyto Ventures. Before NeuBase, Stephan was CEO of LifeX and Chairman and Professor of Human Genetics at the University of Pittsburgh. Prior, he was founding Chairman of the Neurogenomics Division at the Translational Genomics Research Institute. Stephan has founded or co-founded 14 biotechnology companies and advised many others. Stephan was co-founder of Navigenics, a personal genetics company.
Brandon Ross Colby is an American medical geneticist in Beverly Hills, California and physician specializing in predictive medicine and genetic testing. He is author of Outsmart Your Genes, a book about genetics published in 2011, and he is the founder and CEO of direct-to-consumer genetic testing service Sequencing.
Linda Avey is an American biologist and entrepreneur. She is known for co-founding 23andMe, a consumer genetic data company.
Gene by Gene is a commercial genetic testing company based in Houston, Texas. The company was owned by Bennett Greenspan and Max Blankfeld, and was the parent company of Family Tree DNA. In January 2021, Gene by Gene was acquired by US based parent company myDNA Inc. Gene by Gene and Australia company myDNA Life Private Ltd. are both subsidiaries of parent company, myDNA Inc. The current Chief Executive Officer of myDNA Inc. is, Dr Lior Rauchberger.
A biological patent is a patent on an invention in the field of biology that by law allows the patent holder to exclude others from making, using, selling, or importing the protected invention for a limited period of time. The scope and reach of biological patents vary among jurisdictions, and may include biological technology and products, genetically modified organisms and genetic material. The applicability of patents to substances and processes wholly or partially natural in origin is a subject of debate.
openSNP is an open source website where users can share their genetic information. Users upload their genes, including gender, age, eye color, medical history, Fitbit data. With a focus on user patient-led research (PLR), there is potential to redefine the way health research is conducted.
"It promises to be a vital supplement to standard research: it can focus on conditions that are neglected by standard research, such as rare diseases or side effects, and can draw on a broader range of data and deliver outcomes more rapidly. It can also be a way of realising valuable forms of social interaction and support in cases where members of a community conduct PLR together, for example, patients suffering from the same illness."
Genetic privacy involves the concept of personal privacy concerning the storing, repurposing, provision to third parties, and displaying of information pertaining to one's genetic information. This concept also encompasses privacy regarding the ability to identify specific individuals by their genetic sequence, and the potential to gain information on specific characteristics about that person via portions of their genetic information, such as their propensity for specific diseases or their immediate or distant ancestry.
Color Health, Inc. makes population-scale cancer detection and care accessible, convenient, and cost-effective for employers, health plans, and unions. With nearly a decade of experience, Color has served millions of patients and partnered with innovators such as the National Institutes of Health, the CDC, large public health departments, and more.